Faeth Therapeutics Inc FTH

$10.03 -0.62 (-5.82%)

Valuation

Market cap
259,215,000
Revenue TTM
$0
Net income TTM
$-21,090,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
1,040,500
Avg volume
532,222
Day's range
$9.67 – $10.63
Shares out
25,844,000
Stochastic %K
3%
Beta
-0.15
Analysts
Strong Buy
Price target
$55.42

Price

Company profile

Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the...

Show more

Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. The company was formerly known as Sensei Biotherapeutics, Inc. and changed its name to Faeth Therapeutics, Inc. in June 2026. The company was incorporated in 1999 and is headquartered in Rockville, Maryland.

Industry
Biotechnology
Sector
Healthcare
Phone
240 243 8000
Website
https://www.faeththerapeutics.com
Address
1405 Research Boulevard, Suite 125, Rockville, United States

Latest news

Stocktwits

Benalish Nov 13, 9:25 PM
$FTH Hedge funds buying millions of shares! https://www.sec.gov/Archives/edgar/data/1829802/000091957426007764/xslSCHEDULE_13G_X02/primary_doc.xml
0 replies
Struin Nov 12, 5:08 PM
$FTH The analysts consider the decline in Faeth to be completely disproportionate and are maintaining their price targets of around $60. I have never seen analysts defend a company like this before—usually, they tend to be critical. That says it all... I’ve loaded up on shares while they were under $12.
0 replies
MesserschmittBavaria Nov 10, 9:00 PM
$FTH 8,80 it is the target The picture is a left head and shoulder
0 replies
MesserschmittBavaria Nov 10, 8:54 PM
$FTH something is wrong here….
0 replies
MesserschmittBavaria Nov 10, 8:53 PM
$FTH pump the target and they sell ….
0 replies
Struin Nov 10, 6:39 PM
$FTH Faeth Therapeutics stock rating reiterated at Buy $60 by H.C. Wainwright Analyst Ratings Published Nov 10, 2026, 07:20 AM
0 replies
Struin Nov 10, 3:01 PM
$FTH look at the PT's $55-60! No one changed the PT's
0 replies
Quantumup Nov 10, 11:41 AM
$FTH all a/o y'day BTIG: Buy-$55 ~views the dip as a buying opp. [CELC RLAY NVS RHHBY AZN] H.C. Wainwright: Buy-$60 ~would use weakness to build positions—calls selloff overdone. Lucid Capital: Buy-$59 ~views selloff as disproportionate—while the headline ORR was broadly in the range of emerging ADC's rather than clearly superior, the broader dataset is more encouraging, with 16 pts remaining on Tx. TD Cowen: Buy: PIKTOR achieved a 33% ORR and 7.4-month mPFS, clearly exceeding the chemo bar (~15% ORR; 3-4 months). While ORR missed investors' 40% bar, it could improve, and mPFS offsets as it is competitive with sac-TMT. We believe the orthogonal MoA supports Phase III development and an attractive 2L+ EC role. The low hyperglycemia (12%) and stomatitis (21%) rates derisk the larger BC opportunity.
0 replies